PGI2 augments Treg function
PGI2 增强 Treg 功能
基本信息
- 批准号:9896755
- 负责人:
- 金额:$ 53.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-20 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAllergensAllergicAllergic DiseaseAllergic inflammationAnimal ModelAntigensAsthmaCell surfaceCellsClinicalDataDefectDevelopmentEpoprostenolEquilibriumFDA approvedFOXP3 geneGoalsHumanHypersensitivityImmune ToleranceImmune responseImpairmentInterleukin-10Interleukin-13Interleukin-2Interleukin-5Knockout MiceLinkLungLung diseasesMaintenanceMediatingModelingMusPathogenicityPatientsPharmacologyPhenotypeProductionPublishingPulmonary HypertensionReceptor SignalingRegulatory T-LymphocyteReporterReportingSignal TransductionSurfaceTestingTherapeuticThymus GlandTransforming Growth Factor betaanalogclinically significantcytokineexperimental studyimmune system functionin vivoin vivo Modelnovelpathogenpreventreceptorresponse
项目摘要
An optimally functioning immune system requires a balance between protective responses against
environmental pathogens and tolerogenic responses to innocuous environmental antigens. The breakdown of
tolerance to harmless environmental antigens results in antigens becoming allergens that induce allergic
inflammation and disease. Regulatory T cells (Treg) are central to the development and maintenance of
tolerance to allergens; however, the mechanisms by which Treg fail to support tolerance in patients with
allergic disease are not fully defined. In this application, our preliminary data strongly support that a host's
inability to signal through the prostaglandin (PG)I2 receptor impedes immune tolerance and that treatment with
PGI2 analogs promotes tolerance. Specifically, we found that defective PGI2 signaling in thymic Treg (tTreg)
resulted in decreased Foxp3 expression, reduced suppressive function, inhibited IL-10 production, and
downregulated inducible Treg (iTreg) differentiation. We also showed that Treg from mice deficient in the PGI2
receptor IP (IP KO) mice did not suppress type 2 cytokine production in an in vivo adoptive transfer model of
allergic inflammation compared to Treg from WT mice. Therefore, our overarching hypothesis is that PGI2
promotes the immunosuppressive functions of Treg. To test this hypothesis, we have two specific aims.
Specific Aim 1 is to determine the ability of endogenous PGI2 signaling to promote Treg function. In this
aim we hypothesize that: a) antigen-specific Treg that have deficient PGI2 signaling have inhibited suppression
of the cardinal features of asthma compared to antigen-specific WT Treg, b) PGI2 signaling promotes Treg
stability in the setting of allergen challenge, and c) PGI2 signaling restrains ST2 expression on Treg, and that a
deficiency of PGI2 signaling corrupts Treg function promoting the development of pathogenic IL-13 expressing
ST2+ Treg. Specific Aim 2 is to determine the ability of exogenous PGI2 signaling to promote Treg
function. In this aim we hypothesize that: a) PGI2 analog treatment of Treg ex vivo enhances the ability of
iTreg to restrain allergic inflammation, b) exogenous administration of a PGI2 analog increases Treg function to
suppress allergic inflammation, and c) PGI2 analogs enhance IL-10 production and suppressive function by
human iTreg in response to activation with IL-2 and TGF-β. These studies are paradigm shifting because
there are currently no known pharmacologic agents which promote Treg function and our preliminary data
strongly supports that PGI2 may be the first described. The proposed experiments using human cells and mice
will advance the field in that they will further define the mechanisms by which Treg function is regulated. The
current availability of PGI2 for human treatment highlights the clinical significance of our studies as this
therapy could be immediately repurposed for the treatment of allergic respiratory diseases such as asthma.
一个功能最佳的免疫系统需要在保护性反应之间取得平衡,
环境病原体和对无害环境抗原的耐受性应答。破裂
对无害的环境抗原的耐受性导致抗原成为过敏原,
炎症和疾病。调节性T细胞(Treg)是发展和维持免疫系统的核心。
对过敏原的耐受性;然而,Treg不能支持过敏原患者耐受性的机制,
过敏性疾病没有完全定义。在这个应用中,我们的初步数据强烈支持宿主的
不能通过前列腺素(PG)I2受体发出信号阻碍免疫耐受,
PGI 2类似物促进耐受性。具体来说,我们发现胸腺Treg(tTreg)中PGI 2信号缺陷
导致Foxp 3表达降低,抑制功能降低,抑制IL-10产生,
下调诱导型Treg(iTreg)分化。我们还发现,来自PGI 2缺陷小鼠的Treg
受体IP(IP KO)小鼠在体内过继转移模型中没有抑制2型细胞因子的产生。
与来自WT小鼠的Treg相比的过敏性炎症。因此,我们的总体假设是,PGI 2
促进Treg的免疫抑制功能。为了验证这一假设,我们有两个具体目标。
具体目标1是确定内源性PGI 2信号传导促进Treg功能的能力。在这
我们假设:a)具有缺陷的PGI 2信号传导的抗原特异性Treg具有抑制性抑制,
与抗原特异性WT Treg相比,哮喘的主要特征,B)PGI 2信号传导促进Treg
在过敏原激发的情况下的稳定性,以及c)PGI 2信号传导抑制Treg上的ST 2表达,并且
PGI 2信号传导缺陷破坏Treg功能,促进致病性IL-13表达的发展,
ST2+ Treg.具体目标2是确定外源性PGI 2信号传导促进Treg的能力
功能在这个目标中,我们假设:a)Treg的PGI 2类似物离体处理增强了Treg表达的能力。
iTreg抑制过敏性炎症,B)外源性给予PGI 2类似物增加Treg功能,
抑制过敏性炎症,和c)PGI 2类似物通过以下方式增强IL-10产生和抑制功能:
人iTreg对IL-2和TGF-β活化的响应。这些研究是范式转变,因为
目前还没有已知的促进Treg功能的药物,我们的初步数据显示,
强烈支持PGI 2可能是第一个被描述的。使用人类细胞和小鼠进行的拟议实验
将推进该领域,因为他们将进一步定义调节Treg功能的机制。的
目前PGI 2用于人类治疗的可用性突出了我们研究的临床意义,
该疗法可以立即重新用于治疗过敏性呼吸道疾病如哮喘。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ray Stokes Peebles其他文献
Ray Stokes Peebles的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ray Stokes Peebles', 18)}}的其他基金
Viral and Host Determinants of Infant and Childhood Allergy and Asthma
婴儿和儿童过敏和哮喘的病毒和宿主决定因素
- 批准号:
10230389 - 财政年份:2020
- 资助金额:
$ 53.56万 - 项目类别:
Viral and Host Determinants of Infant and Childhood Allergy and Asthma
婴儿和儿童过敏和哮喘的病毒和宿主决定因素
- 批准号:
10301919 - 财政年份:2020
- 资助金额:
$ 53.56万 - 项目类别:
PGI2 inhibition of pulmonary innate allergic immune responses
PGI2 抑制肺部先天过敏性免疫反应
- 批准号:
10046277 - 财政年份:2018
- 资助金额:
$ 53.56万 - 项目类别:
PGI2 inhibition of pulmonary innate allergic immune responses
PGI2 抑制肺部先天过敏性免疫反应
- 批准号:
10292947 - 财政年份:2018
- 资助金额:
$ 53.56万 - 项目类别:
PGI2 regulation of CD4+ Th2 metabolism in allergic airway inflammation
PGI2 对过敏性气道炎症中 CD4 Th2 代谢的调节
- 批准号:
10696335 - 财政年份:2018
- 资助金额:
$ 53.56万 - 项目类别:
PGI2 inhibition of pulmonary innate allergic immune responses
PGI2 抑制肺部先天过敏性免疫反应
- 批准号:
9924242 - 财政年份:2018
- 资助金额:
$ 53.56万 - 项目类别:
PGI2 regulation of TSLP-mediated allergic inflammation in the lung
PGI2 对 TSLP 介导的肺部过敏性炎症的调节
- 批准号:
9252369 - 财政年份:2014
- 资助金额:
$ 53.56万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 53.56万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 53.56万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 53.56万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 53.56万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 53.56万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 53.56万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 53.56万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 53.56万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 53.56万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 53.56万 - 项目类别: